Sign In
Buy ADAP
$0.0549
+0 (+0%)
At Close: Feb 20, 2026
Adaptimmune Therapeutics plc (ADAP) Q3 2024 Earnings Call Transcript
07:48pm, Wednesday, 13'th Nov 2024
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Dan Od-Cohen - IR Adrian Rawcliffe - CEO Gavin Wood - CFO Dennis Williams
Adaptimmune Reports Q3 2024 Financial and Business Updates
04:05pm, Wednesday, 13'th Nov 2024
Tecelra® launch on track with 9 Authorized Treatment Centers available to initiate patient treatment journey, and the first patient apheresed in Q3; expect first commercial revenues in Q4 and the num
Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial
09:00am, Wednesday, 13'th Nov 2024
42% of people with advanced or metastatic synovial sarcoma or MRCLS had clinical responses with lete-cel Results include six complete responses (6/64); twenty-one partial responses (21/64) Data to be
Adaptimmune to Participate in Scientific and Medical Conferences this November and December
09:19am, Tuesday, 05'th Nov 2024
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 5, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor can
Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024
05:20pm, Thursday, 31'st Oct 2024
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - October 31, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with
Adaptimmune to Participate in Two Bank Conferences this September
08:00am, Wednesday, 28'th Aug 2024
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 28, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor can
Adaptimmune Therapeutics plc (ADAP) Q2 2024 Earnings Call Transcript
11:42am, Monday, 12'th Aug 2024
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q2 2024 Earnings Conference Call August 12, 2024 8:00 AM ET Company Participants Dan Od-Cohen - Investor Relations Adrian Rawcliffe - Chief Executive Office
Adaptimmune Reports Q2 2024 Financial and Business Updates
07:00am, Monday, 12'th Aug 2024
Adaptimmune received U.S. FDA accelerated approval of Tecelra® (afami-cel), the first approved engineered cell therapy for a solid tumor Patients can begin treatment journey; biomarker testing availa
Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024
08:00am, Monday, 05'th Aug 2024
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 5, 2024) - Adaptimmune Therapeutics plc (Nasdaq: ADAP), a company redefining the treatment of solid tumor cancers with c
US FDA approves Adaptimmune's gene therapy for rare type of cancer
09:20am, Friday, 02'nd Aug 2024
The U.S. Food and Drug Administration said on Friday it has approved Adaptimmune's first-of-its-kind gene therapy to treat adult patients with a rare type of cancer that affects soft tissues who have
STM Investors Have Opportunity to Join STMicroelectronics N.V. Fraud Investigation with the Schall Law Firm
10:56pm, Thursday, 01'st Aug 2024
LOS ANGELES--(BUSINESS WIRE)--STM Investors Have Opportunity to Join STMicroelectronics N.V. Fraud Investigation with the Schall Law Firm.
PHILADELPHIA & OXFORD, England--(BUSINESS WIRE)--Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced U.S.
Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024
09:54am, Wednesday, 03'rd Jul 2024
Adaptimmune Therapeutics is focused on late-stage development of cell therapy for cancer, particularly in sarcoma management. Pipeline updates include progress on afami-cel for soft tissue sarcomas an
ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company
02:05pm, Monday, 17'th Jun 2024
By Michael Kim
Overall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response at time of analysis Interim analysis data reinforces the pote
